Bionano Genomics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
BNGO$1.23+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Stockholders’ Equity (Deficit)
| AdditionalPaid-inCapital · AccumulatedDeficit · Accumulated Other Comprehensive Income (Loss) · TotalStockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock | |||||||
| Shares · Amount | |||||||
| Balance at January 1, 2022 | 28,960,000 | $3,000 | $553,773,000 | $(216,119,000) | $(539,000) | $337,118,000 | |
| Stock option exercises | 47,000 | — | 343,000 | — | — | 343,000 | |
| Stock-based compensation expense | — | — | 22,417,000 | — | — | 22,417,000 | |
| Issue common stock, net of issuance costs | 664,000 | — | 22,551,000 | — | — | 22,551,000 | |
| Issue stock for employee stock purchase plan | 30,000 | — | 150,000 | — | — | 150,000 | |
| Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes | 17,000 | — | — | — | — | — | |
| Issue stock for acquisition | — | — | — | — | |||
| Net loss | — | — | — | (132,596,000) | — | (132,596,000) | |
| Other comprehensive loss | — | — | — | — | (585,000) | (585,000) | |
| Balance at December 31, 2022 | 29,718,000 | $3,000 | $599,234,000 | $(348,715,000) | $(1,124,000) | $249,398,000 | |
| Stock option exercises | 4,000 | — | 23,000 | — | — | 23,000 | |
| Stock-based compensation expense | — | — | 15,178,000 | — | — | 15,178,000 | |
| Issue common stock, net of issuance costs | 12,507,000 | 1,000 | 56,313,000 | — | — | 56,314,000 | |
| Issue stock for employee stock purchase plan | 30,000 | — | 108,000 | — | — | 108,000 | |
| Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes | 1,000 | — | (61,000) | — | — | (61,000) | |
| Issuance of common stock for convertible notes payable | 3,492,000 | 1,000 | 6,542,000 | — | — | 6,543,000 | |
| Net loss | — | — | — | (232,493,000) | — | (232,493,000) | |
| Other comprehensive income | — | — | — | — | 1,147,000 | 1,147,000 | |
| Balance at December 31, 2023 | 45,752,000 | $5,000 | $677,337,000 | $(581,208,000) | $23,000 | $96,157,000 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.